I am a
Home I AM A Search Login

Papers of the Week

Papers: 4 Jan 2020 - 10 Jan 2020

Pharmacology/Drug Development

2020 01 06

Annu Rev Pharmacol Toxicol


Editor's Pick

Neuropathic Pain: Mechanism-Based Therapeutics.


Bannister K, Sachau J, Baron R, Dickenson AH
Annu Rev Pharmacol Toxicol. 2020 01 06; 60:257-274.
PMID: 31914896.


Neuropathic pain (NeP) can result from sources as varied as nerve compression, channelopathies, autoimmune disease, and incision. By identifying the neurobiological changes that underlie the pain state, it will be clinically possible to exploit mechanism-based therapeutics for maximum analgesic effect as diagnostic accuracy is optimized. Obtaining sufficient knowledge regarding the neuroadaptive alterations that occur in a particular NeP state will result in improved patient analgesia and a mechanism-based, as opposed to a disease-based, therapeutic approach to facilitate target identification. This will rely on comprehensive disease pathology insight; our knowledge is vastly improving due to continued forward and back translational preclinical and clinical research efforts. Here we discuss the clinical aspects of neuropathy and currently used drugs whose mechanisms of action are outlined alongside their clinical use. Finally, we consider sensory phenotypes, patient clusters, and predicting the efficacy of an analgesic for neuropathy.